Evolving concepts in the quantitative analysis of the determinants of the plasma water sodium concentration and the pathophysiology and treatment of the.

Slides:



Advertisements
Similar presentations
A Clinical Approach to the Treatment of Chronic Hypernatremia
Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Nina Vasavada, Rajiv Agarwal  Kidney International 
Pathophysiology of renal fluid retention
Volume 54, Issue 2, Pages (August 1998)
Plasma sodium and hypertension
Volume 70, Issue 3, Pages (August 2006)
Diagnosis and Treatment of Hyponatremia
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Seeing the sodium in a patient with hypernatremia
Making sense of the sensor: Mysteries of the macula densa
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Volume 67, Issue 2, Pages (February 2005)
Dieter A. Häberle, Wolfgang Biller, Takuyuki Ise, Christian J. Metz 
Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating  Wim Van Biesen, Achim Jörres  Kidney International 
Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding  Kidney International 
George A. Kaysen, Burl R. Don
Urea for hyponatremia? Kidney International
Monitoring Urine Flow to Prevent Overcorrection of Hyponatremia: Derivation of a Safe Upper Limit Based on the Edelman Equation  Florian Buchkremer, MD,
Methotrexate in the urine
S.G. John, N.M. Selby, C.W. McIntyre  Kidney International 
Proinflammatory effects of iron sucrose in chronic kidney disease
Measuring transport of water across the peritoneal membrane
Overcorrection of hyponatremia is a medical emergency
The epidemiology of chronic kidney disease
Volume 87, Issue 2, Pages (February 2015)
Volume 71, Issue 11, Pages (June 2007)
Volume 95, Issue 2, Pages (February 2019)
Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure  A. Parikova, W. Smit, D.G. Struijk,
Volume 73, Issue 9, Pages (May 2008)
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier
Volume 74, Issue 8, Pages (October 2008)
Methods for guideline development
Volume 85, Issue 1, Pages 3-4 (January 2014)
Atrial fibrillation in end-stage renal disease: an emerging problem
Extracorporeal removal of toxins
Nephrology Crossword: Glomerulonephritis
Volume 71, Issue 4, Pages (February 2007)
Volume 79, Issue 2, Pages (January 2011)
Volume 81, Issue 4, Pages (February 2012)
A man with a hole in his penis
Fibroblast growth factor 23: the making of a hormone
Volume 73, Issue 9, Pages (May 2008)
Volume 82, Issue 9, Pages (November 2012)
Volume 68, Issue 5, Pages (November 2005)
Volume 71, Issue 9, Pages (May 2007)
Medical Treatment of Overactive Bladder: In Response
Volume 74, Issue 9, Pages (November 2008)
Peter G. Blake, Arsh K. Jain, Sechelle Yohanna  Kidney International 
Organ transplantation goes to the movies
Nina Vasavada, Rajiv Agarwal  Kidney International 
Volume 69, Issue 1, Pages (January 2006)
Volume 80, Issue 10, Pages (November 2011)
Charles A. Herzog  Kidney International 
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
ANCA comes of age—but with caveats
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate  S. Aime, C. Canavese, P. Stratta  Kidney International 
Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller 
H.J. Chin, H. Ro, H.J. Lee, K.Y. Na, D.-W. Chae  Kidney International 
III. Treating dyslipidemias
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Where vaptans do and do not fit in the treatment of hyponatremia
Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga 
Volume 58, Issue 5, Pages (November 2000)
Volume 60, Issue 5, Pages (November 2001)
Horacio J. Adrogué, Nicolaos E. Madias 
Presentation transcript:

Evolving concepts in the quantitative analysis of the determinants of the plasma water sodium concentration and the pathophysiology and treatment of the dysnatremias  I.R.A. Kurtz, Minhtri K. Nguyen  Kidney International  Volume 68, Issue 5, Pages 1982-1993 (November 2005) DOI: 10.1111/j.1523-1755.2005.00652.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Schematic diagram depicting the complexity of factors that modulate the [Na+]pw. At any given time point, all the terms in equation 4 determine the value of the [Na+]pw. The magnitude of the terms in equation 4 is altered by changes in the mass balance of Na+, K+, non-Na+ non-K+ osmoles, H2O, and subsequent intercompartmental water shifts. Kidney International 2005 68, 1982-1993DOI: (10.1111/j.1523-1755.2005.00652.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Quantitative effect of the slope and y intercept in the Edelman equation on the [Na+]pw. The slope of 1.11 and y intercept of -25.6 in the Edelman equation are determined by several parameters that have physiologic and clinical significance. The quantitative significance of the slope and y intercept in the Edelman equation can be graphically depicted by comparing the value of [Na+]pw (mmol/L) at a given (Nae + Ke)/TBW (mmol/L) as calculated according to the abbreviated form of the equation: [Na+]pw = (Nae + Ke)/TBW (upper line) and the complete equation [Na+]pw = 1.11(Nae + Ke)/TBW - 25.6 (lower line). Kidney International 2005 68, 1982-1993DOI: (10.1111/j.1523-1755.2005.00652.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 (A) Dependence of the [Na+]p on the plasma glucose concentration as calculated according to [Na+]p = 1.03(Nae + Ke)/TBW - 23.8 - (1.6/100) ([glucose]p - 120). The formula demonstrates that the value of the y intercept changes in hyperglycemia. An increase in the plasma glucose concentration results in a predictable increase in the magnitude of the y intercept, thereby decreasing the [Na+]p (mmol/L). Upper line is glucose 120 mg/dL; middle line is glucose 500 mg/dL; and lower line is glucose 1000 mg/dL. (B) Theoretical dependence of the y intercept on the [glucose]p. Hyperglycemia causes an intercompartmental water shift, resulting in a change in the value of several of the parameters in the y intercept of equation 4. The theoretical dependence of the magnitude of the y intercept on the [glucose]p is depicted. Kidney International 2005 68, 1982-1993DOI: (10.1111/j.1523-1755.2005.00652.x) Copyright © 2005 International Society of Nephrology Terms and Conditions